Department of Radiation Oncology, College of Medicine, Catholic University of Korea, Seoul, Korea.
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1073-80. doi: 10.1016/j.ijrobp.2009.09.009. Epub 2010 Mar 6.
To identify the parameters that predict hepatic toxicity and deterioration of hepatic function.
A total of 47 patients with small unresectable primary hepatocellular carcinoma received hypofractionated stereotactic body radiotherapy (SBRT) using the CyberKnife. Of those, 36 patients received no other local treatments that could influence hepatic toxicity at least for 3 months after the completion of SBRT. The gross tumor volume (GTV) was 18.3 ± 15.9 cm(3) (range, 3.0-81.3 cm(3)), and the total dose administered was 30-39 Gy (median, 36 Gy). To assess the deterioration of hepatic function, we evaluated the presence or absence of the progression of Child-Pugh class (CP class). To identify the parameters of predicting the radiation-induced hepatic toxicity and deterioration of the hepatic function, several clinical and dose-volumetric parameters were evaluated.
Of 36 patients, 12 (33%) developed Grade 2 or higher hepatic toxicity and 4 (11%) developed progression of CP class. The multivariate analysis showed that the only significant parameter associated with the progression of CP class was the total liver volume receiving a dose less than 18 Gy (<18 Gy).
The progression of CP class after SBRT limits other additional local treatments and also reflects the deterioration of hepatic function. Therefore, it would be important to note that the presence or absence of the progression of CP class is a dose-limiting factor. The total liver volume receiving <18 Gy should be greater than 800 cm(3) to reduce the risk of the deterioration of hepatic function.
确定预测肝毒性和肝功能恶化的参数。
共 47 例不能手术的小肝癌患者接受 CyberKnife 立体定向体部放射治疗(SBRT)。其中,36 例患者在 SBRT 完成后至少 3 个月内未接受任何可能影响肝毒性的其他局部治疗。肿瘤总体积(GTV)为 18.3 ± 15.9 cm³(范围:3.0-81.3 cm³),给予的总剂量为 30-39 Gy(中位数:36 Gy)。为评估肝功能恶化,我们评估了 Child-Pugh 分级(CP 分级)是否进展。为了确定预测放射性肝毒性和肝功能恶化的参数,评估了几个临床和剂量体积参数。
36 例患者中,12 例(33%)发生 2 级或以上肝毒性,4 例(11%)发生 CP 分级进展。多变量分析显示,与 CP 分级进展唯一相关的显著参数是接受剂量小于 18 Gy(<18 Gy)的总肝体积。
SBRT 后 CP 分级的进展限制了其他额外的局部治疗,也反映了肝功能的恶化。因此,注意 CP 分级的进展是否存在是一个剂量限制因素是很重要的。接受<18 Gy 的总肝体积应大于 800 cm³,以降低肝功能恶化的风险。